Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

Zydus Lifesciences Limited

Zydus Lifesciences Ltd. is a global lifesciences company focused on delivering care and support for patients, backed by innovation and science.

msh id	COM:ZYDUSLIFE
symbol	ZYDUSLIFE
name	Zydus Lifesciences Limited
homepage url	https://www.zyduslife.com
country	IN
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	23.03K
crunchbase url	-
linkedin url	-
founders	-

market cap	13.92B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.14
growth cost of revenue	0.08
growth depreciation and amortization	-0.02
growth ebitda	0.18
growth ebitda ratio	0.04
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.36
growth gross profit	0.17
growth gross profit ratio	0.03

COM:ZYDUSLIFE

Zydus Lifesciences Ltd.

Last Close

947.60

21/11 10:00

Market Cap

1.17T

Beta: -

Volume Today

622.85K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.48B
cost of revenue	1.48B
depreciation and amortization	88.16M
ebitda	410.57M
ebitda ratio	0.23
eps	0.27
eps diluted	0.27
operating expenses	782.28M
operating income	322.41M
operating income ratio	0.18

accounts receivables	-101.62M
capital expenditure	-123.46M
cash at beginning of period	132.56M
cash at end of period	68.64M
inventory	445.44M
working capital ttm	55.72B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-